Clinical trial
Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides
NCT00400101 · Swiss Tropical & Public Health Institute, Other · Terminated
Key facts
| NCT number | NCT00400101 |
|---|---|
| Title | Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides |
| Official title | A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers |
| Lead sponsor | Swiss Tropical & Public Health Institute, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Falciparum Malaria |
| Intervention type | Biological |
| Interventions | Virosome-formulated synthetic peptides (malaria vaccine) |
| Enrollment | 46 |
| Start date | Nov 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Nov 16, 2006 |
| Last update posted | Nov 16, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: